24.02
14.69%
+3.0774
Xencor Inc stock is currently priced at $24.02, with a 24-hour trading volume of 1.31M.
It has seen a +14.69% increased in the last 24 hours and a +9.56% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $21.12 pivot point. If it approaches the $22.81 resistance level, significant changes may occur.
Previous Close:
$20.94
Open:
$20.97
24h Volume:
1.31M
Market Cap:
$1.46B
Revenue:
$168.34M
Net Income/Loss:
$-126.09M
P/E Ratio:
-11.22
EPS:
-2.14
Net Cash Flow:
$63.86M
1W Performance:
+26.26%
1M Performance:
+9.56%
6M Performance:
+37.47%
1Y Performance:
-11.28%
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
111 West Lemon Avenue, 2nd Floor, Monrovia, CA
Xencor Inc Stock (XNCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-19-23 | Initiated | BofA Securities | Buy |
Dec-06-22 | Initiated | Cowen | Outperform |
Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Jan-21-22 | Initiated | SMBC Nikko | Outperform |
Dec-15-21 | Initiated | H.C. Wainwright | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Mar-04-20 | Initiated | Barclays | Underweight |
Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
Nov-20-19 | Resumed | Guggenheim | Neutral |
Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jun-13-19 | Initiated | Mizuho | Buy |
Apr-12-19 | Initiated | Guggenheim | Buy |
Mar-27-19 | Initiated | Berenberg | Buy |
Mar-15-19 | Initiated | Raymond James | Outperform |
Sep-10-18 | Resumed | BTIG Research | Buy |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Mar-02-17 | Initiated | Instinet | Neutral |
Mar-02-17 | Reiterated | Wedbush | Outperform |
Oct-04-16 | Initiated | Piper Jaffray | Overweight |
Dec-22-15 | Initiated | Canaccord Genuity | Buy |
Aug-05-15 | Reiterated | MLV & Co | Buy |
Feb-12-15 | Reiterated | Oppenheimer | Outperform |
Jan-28-15 | Reiterated | MLV & Co | Buy |
Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Analyst Scoreboard: 6 Ratings For Xencor
Benzinga
Unveiling 4 Analyst Insights On Xencor
Benzinga
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
Zacks Investment Research
Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Zacks Investment Research
Navigating 4 Analyst Ratings For Xencor
Benzinga
Xencor Inc Stock (XNCR) Financials Data
Xencor Inc (XNCR) Revenue 2024
XNCR reported a revenue (TTM) of $168.34 million for the quarter ending December 31, 2023, a +2.28% rise year-over-year.
Xencor Inc (XNCR) Net Income 2024
XNCR net income (TTM) was -$126.09 million for the quarter ending December 31, 2023, a -128.49% decrease year-over-year.
Xencor Inc (XNCR) Cash Flow 2024
XNCR recorded a free cash flow (TTM) of $63.86 million for the quarter ending December 31, 2023, a +437.54% increase year-over-year.
Xencor Inc (XNCR) Earnings per Share 2024
XNCR earnings per share (TTM) was -$2.10 for the quarter ending December 31, 2023, a -125.81% decline year-over-year.
Xencor Inc Stock (XNCR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Desjarlais John R | SR. VICE PRESIDENT & CSO |
Mar 11 '24 |
Sale |
23.50 |
1,280 |
30,082 |
186,433 |
Eckert Celia | SVP, GENERAL COUNSEL |
Mar 11 '24 |
Sale |
23.50 |
850 |
19,977 |
45,465 |
Kuch John J | SR. VICE PRESIDENT & CFO |
Mar 11 '24 |
Sale |
23.50 |
849 |
19,953 |
121,070 |
GUSTAFSON KURT A | Director |
Mar 06 '24 |
Option Exercise |
10.73 |
15,000 |
160,950 |
20,007 |
GUSTAFSON KURT A | Director |
Mar 06 '24 |
Sale |
23.18 |
14,000 |
324,453 |
6,007 |
Dahiyat Bassil I | PRESIDENT & CEO |
Mar 05 '24 |
Sale |
23.43 |
12,528 |
293,519 |
300,097 |
Desjarlais John R | SR. VICE PRESIDENT & CSO |
Mar 05 '24 |
Sale |
23.43 |
6,629 |
155,311 |
166,989 |
Kuch John J | SR. VICE PRESIDENT & CFO |
Mar 05 '24 |
Sale |
23.43 |
4,474 |
104,821 |
121,919 |
Eckert Celia | SVP, GENERAL COUNSEL |
Mar 05 '24 |
Sale |
23.43 |
3,892 |
91,186 |
33,226 |
Desjarlais John R | SR. VICE PRESIDENT & CSO |
Feb 14 '24 |
Option Exercise |
11.05 |
11,943 |
131,970 |
173,618 |
About Xencor Inc
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.
Cap:
|
Volume (24h):